

This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety

International Archives of Medicine 2012, **5**:5 doi:10.1186/1755-7682-5-5

Jorge Paz Rodriguez (drpaz@cellmedicine.com)
Michael P Murphy (mipmurph@iupui.edu)
Soonjun Hong (psyche94@gmail.com)
Marialaura Madrigal (marialaura@cellmedicine.com)
Keith L March (kmarch@iupui.edu)
Boris Minev (bminev@ucsd.edu)
Robert J Harman (bharman@vet-stem.com)
Chien-Shing Chen (CSchen@llu.edu)
Ruben Berrocal Timmons (info@senacyt.gob.pa)
Annette M Marleau (amarleau@immed.org)
Neil H Riordan (nhriordan@gmail.com)

ISSN 1755-7682

Article type Review

Submission date 8 December 2011

Acceptance date 8 February 2012

Publication date 8 February 2012

Article URL <http://www.intarchmed.com/content/5/1/5>

This peer-reviewed article was published immediately upon acceptance. It can be downloaded, printed and distributed freely for any purposes (see copyright notice below).

Articles in *International Archives of Medicine* are listed in PubMed and archived at PubMed Central.

For information about publishing your research in *International Archives of Medicine* or any BioMed Central journal, go to

<http://www.intarchmed.com/authors/instructions/>

For information about other BioMed Central publications go to

© 2012 Paz Rodriguez *et al.*; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

<http://www.biomedcentral.com/>

Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety

ArticleCategory	:	Review
ArticleHistory	:	Received: 08-Dec-2011; Accepted: 21-Jan-2012
ArticleCopyright	:	© 2012 Paz Rodriguez et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jorge Paz Rodriguez,^{Aff1}
Email: drpaz@cellmedicine.com

Michael P Murphy,^{Aff2}
Email: mipmurph@iupui.edu

Soonjun Hong,^{Aff2}
Email: psyche94@gmail.com

Marialaura Madrigal,^{Aff1}
Email: marialaura@cellmedicine.com

Keith L March,^{Aff2}
Email: kmarch@iupui.edu

Boris Minev,^{Aff3}
Email: bminev@ucsd.edu

Robert J Harman,^{Aff4}
Email: bharman@vet-stem.com

Chien-Shing Chen,^{Aff5}
Email: CSchen@llu.edu

Ruben Berrocal Timmons,^{Aff6}
Email: info@senacyt.gob.pa

Annette M Marleau,^{Aff7}
Corresponding Affiliation: Aff7
Phone: 858 997 9435
Email: amarleau@immed.org

Neil H Riordan,^{Aff1}
Email: nhriordan@gmail.com

Aff1 Medistem Panama, Panama City, Panama

Aff2 Indiana University, Indiana, USA

Aff3 University of San Diego, San Diego, CA, USA

Aff4 Vet-Stem Inc, Poway, CA, USA

Aff5 Division of Hematology and Oncology, Loma Linda University,
School of Medicine, Loma Linda, CA, USA

Aff6 Senacyt, Panama City, Panama, USA

Aff7 Institute for Molecular Medicine, Huntington Beach, CA, USA

Abstract

Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.

Introduction

Increasing number of reports support the possibility of utilizing adult stem cell therapy not only for treatment of degenerative conditions, but also as a means of addressing underlying inflammation or autoimmune conditions [1-8]. Unfortunately, stem cell therapy is often complicated by the need for complex laboratories, processing procedures and clean rooms. The potential drawbacks of allogeneic donor approaches include the possibility of eventual rejection of the cellular graft [9-12], as well as limitation of efficacy due to trophic effects but not de novo tissue generation [13-15]. Conversely, adult stem cell based approaches, particularly using bone marrow, are limited to the relatively small number of progenitor cells within the bone marrow. While bone marrow mononuclear cell administration appears to be effective in conditions where cells are locally implanted, such as intramyocardial [16-18], or intramuscular in critical limb ischemia [19-21], the intravenous administration of non-expanded bone marrow has not been performed with efficacy in systemic conditions without prior myeloablation of the recipient. One way of circumventing this problem is to expand autologous stem cells prior to implantation. Unfortunately, besides issues of cost and practicality, there is a risk that the in vitro manipulation could be linked to contamination, as well as genomic alterations of the cells, leading to transformation.

Several studies have used bone marrow derived mesenchymal stem cells (MSC) for various conditions including type 2 diabetes [22], osteoarthritis [23], stroke [24], and amyotrophic lateral sclerosis [25]. This procedure requires expansion of the MSC compartment in vitro and therefore adds an element of complexity to the treatment. A much simpler procedure, for which adipose tissue is uniquely suited, is the administration of autologous, non-expanded cellular fraction. The rationale behind this derives from observations that: a) adipose tissue contains substantially higher numbers of MSC compared to bone marrow [26]; b) MSC from adipose tissue do not appear to decrease in number as a result of age [27,28]; and c) adipose tissue contains unique populations of cells including high concentrations of endothelial

progenitor cells and T regulatory (Treg) cells that express up to 100-fold higher levels of the immune suppressive cytokine IL-10 as compared to circulating Tregs [29].

The adipose stromal vascular fraction (SVF) is comprised of the mononuclear cells derived from adipose tissue. This term is more than 4 decades old, used to describe the mitotically active source of adipocyte precursors [30,31]. SVF as a source of stem cells was first described by Zuk et al. who identified MSC-like cells in SVF that could be induced to differentiate into adipogenic, chondrogenic, myogenic, and osteogenic lineages [32]. Subsequent to the initial description, the same group reported after *in vitro* expansion, the SVF derived cells had surface marker expression similar to bone marrow derived MSC, comprising CD29, CD44, CD71, CD90, CD105/SH2, and SH3 and lacking CD31, CD34, and CD45 expression [33,34].

Reported clinical trials on adipose derived cells, to date, have all utilized *ex vivo* expanded cells, which share properties with bone marrow derived MSC [35-40]. MSC expanded from adipose tissue are equivalent, if not superior to bone marrow in terms of differentiation ability [41,42], angiogenesis stimulating potential [43,44], and immune modulatory effects [45]. Given the requirements and potential contaminations associated with *ex vivo* cellular expansion, a simpler procedure would be the use of primary adipose tissue derived cells for therapy. Indeed, it is reported that over 4000 horses and 4000 dogs with various cartilage and bone injuries have been successfully treated with autologous SVF [46]. In double blind studies of canine osteoarthritis statistically significant improvements in lameness, range of motion, and overall quality of life have been described [47,48].

If such approaches could be translated clinically, an easy-to-use autologous stem cell therapy could be implemented that is applicable to a multitude of indications. Indeed, this is the desire of commercial entities that are developing bench-top closed systems for autologous adipose cell therapy [49,50], which are presently entering clinical trials. Unfortunately, since the majority of scientific studies have focused on *in vitro* expanded adipose derived cells, relatively little is known about the potential clinical effects of the whole lipoaspirate that contains numerous cell populations besides MSC. From a safety perspective the process of autologous fat grafting has been commonly used in cosmetic surgery [51,52]. Therefore, administration of autologous heterogeneous adipose cellular fractions, which contain numerous cellular populations besides MSC, should be relatively innocuous. However, from an efficacy or disease-impact perspective, it is important to consider the various cellular components of adipose tissue and to develop a theoretical framework for evaluating activities that these components may mediate when administered systemically. For example, while attention is focused on the MSC component of adipose tissue, the high concentrations of monocytes/macrophages, and potential impact these may have on a clinical indication is often ignored [29].

In the published literature, the clinical use of systemically administered SVF cells has been reported in two pilot studies by our group. The first was a description of 3 patients suffering from multiple sclerosis who received intravenous administration of autologous adipose SVF as part of a cellular cocktail. All 3 patients reported significant improvement neurologically, and demonstrated an excellent safety profile [53]. Additionally, a 1 patient case report described a remission of RA subsequent to administration of autologous SVF as a monotherapy [29]. Here we will provide a description of adipose SVF components, provide a rationale for use, and describe safety at 1, 3, 6, and 12 months in a 13 patient retrospective analysis.

The MSC component of adipose tissue

MSC are conventionally extracted from bone marrow sources as a cellular therapy for inflammatory associated conditions. Specifically, the most advanced clinical trials in the area of regenerative medicine have been performed by the company Osiris, whose main product is a “universal donor” MSC, termed “Prochymal”[54]. This cellular product has entered Phase III trials in graft versus host disease, and is currently being tested for heart failure [55]. Other bone marrow derived MSC-like products are in clinical trials, for example, Mesoblast is in Phase III assessing its Mesenchymal Precursor Cell for efficacy in post hematopoietic transplant graft failure, as well as in Phase II for heart failure [56]. Therapeutic advantages of MSC include their ability to migrate to injured tissue, in part via detections of hypoxia through the CXCR4-SDF-1 axis [57,58], differentiation activity into multiple tissues [59,60], release of trophic factors[61], inhibition of apoptosis [62-64], stimulation of angiogenesis [65], inhibition of inflammation [66], and stimulation of Treg activity [67]. Despite the advantages of the current approaches, bone marrow contains relatively small numbers of MSC, thus, as previously mentioned, therapeutics with bone marrow for systemic applications requires ex vivo expansion. Specifically, the bone marrow contains approximately 1/10,000 to 1/100,000 MSC per nucleated cells [68], whereas adipose tissue contains approximately 100–1000 fold higher MSC concentration, or approximately 50–100,000 MSC per ml [69]. Given the relative ease of extracting 500 ml of lipoaspirate, it is conceptually feasible to generate a 25–50 million cell dose of MSC, which is close to the systemic doses of MSC that are typically used in clinical trials of allogeneic expanded cells (eg. 50–100 million cells in various clinical trials) [34]. Conceptually, given that the MSC present in the SVF are autologous, one could envision higher therapeutic potential due to the lack of allo-immune clearance as compared to allogeneic MSC, although this needs to be assessed experimentally.

Adipose MSC contain several similarities and differences as compared to bone marrow derived MSC, although this area is still considered to be controversial. Specifically, in animal cardiac infarct models it has been demonstrated that that expanded adipose MSC are superior to bone marrow MSC in terms of stimulating angiogenesis, decreasing cardiac pathology, and stimulating VEGF and FGF secretion [70]. Using an in vivo lentiviral-labeled system, it was demonstrated that adipose derived MSC have a superior ability to BM derived MSC to integrate into cardiac muscle after injury, as well as to restore function [71]. In addition to specific propensities for differentiation, adipose tissue-derived MSC appear to be superior to bone marrow in terms of proliferative potential without loss of telomere length. Vidal et al. demonstrated that adipose MSC could multiply for almost twice as many cell passages without undergoing senescence as compared to bone marrow MSC [72].

Conversely, several authors have reported similarities between bone marrow and SVF MSC sources. For example, subsequent to exposure to chemotactic agents, both sources were reported to yield MSC possessing similar rates of migration [73]. The same study also demonstrated comparable ability to generate cartilage when treated under differentiation conditions. Another study reported exposure of bone marrow or adipose derived MSC to ischemia leads to the release of similar levels of angiogenic factors, as well as resistance to apoptosis when cultured in hypoxic environments [74]. Comparison of immunological properties led to the conclusion that when expanded, both BM and adipose derived MSC appear to have similar properties in terms of suppressing mixed lymphocyte reactions, inhibiting release of type 1 and inflammatory cytokines, as well as generating progeny cells that appear to be relatively immune privileged [75]. These data were confirmed by the group

of Zhang et al. who compared cord blood, bone marrow, and adipose MSC and found almost identical ability to inhibit immune response assays in vitro [76]. In contrast, Najar et al. reported that Wharton Jelly and adipose derived MSC were superior immune suppressors as compared to BM MSC in terms of inhibiting lymphocyte proliferation and type 1 cytokine production [77,78]. An important consideration is that there is a great deal of variability between studies, not only in the tissue sources from which MSC are derived but also in terms of cell isolation, culture and expansion methods as well as donor-specific characteristics that could conceivably influence the activities and differentiation potential of these cells [79]. Therefore, one potential disadvantage of utilizing ex vivo-manipulated MSC is the potential for introducing more heterogeneity in their regenerative capabilities. For treatments involving autologous MSC, patient-to-patient differences in MSC function could also lead to variability in the clinical efficacy of treatments.

Clinically, adipose derived MSC have been used in treatment of 8 spinal cord injury patients in Korea where administration of autologous expanded MSC at doses of 400 million per patient did not elicit treatment associated adverse events during a 3-month follow-up [80]. Additionally, this study also reported genetic stability of MSC in vitro and lack of toxicity or tumorigenicity of MSC in immune deficient mice. Trivedi's group treated 11 patients with type 1 diabetes using a combination of autologous adipose derived MSC that were cultured in a pro-pancreatic differentiation media together with cultured bone marrow MSC. No adverse effects were noted over an average of 23 months follow-up period and a decrease in insulin requirements was noted [81]. Garcia-Olmo et al. reported a study where autologous expanded adipose MSC were administered to patients with complex perianal fistulas, with 35 of cryptoglandular origin and 14 associated with Crohn's disease. They observed that fistula healing occurred in 17 (71 percent) of 24 patients who received ASCs in addition to fibrin glue compared with 4 (16 percent) of 25 patients who received fibrin glue alone (relative risk for healing, 4.43; confidence interval, 1.74–11.27; $P < 0.001$). The proportion of patients with documented fistula healing was similar in Crohn's and non-Crohn's subgroups. ASCs were also more effective than fibrin glue alone in patients with a suprasphincteric fistulous tract ($P = 0.001$). Furthermore, quality of life scores were higher in patients who received ASCs than in those who received fibrin glue alone [82]. Due to the anti-inflammatory effects of MSC in general [83-86], and specifically the ability of MSC to inhibit graft versus host disease (GVHD) [87,88], Fang et al. reported a series of pilot cases in which patients with steroid refractory GVHD was successfully treated by administration of autologous adipose derived expanded MSC [89,90].

Thus it appears that the MSC component of adipose tissue possesses numerous preclinical and clinical therapeutic properties and may be an important component of the SVF cell population that is responsible for therapeutic effects observed after administration.

Adipose tissue resident T regulatory (treg) cells

Treg cells are conventionally described as CD4+ cells possessing the transcription factor FoxP3 and capable of suppressing T cell activation, dendritic cell maturation, neutrophil activation, and antibody production. The fundamental role of Treg in controlling immunity can be illustrated by the fact that genetic mutations associated with loss of Treg function, such as FoxP3 mutations, are associated with autoimmunity in mouse and man [91-93]. Additionally, conditional ablation of the Treg compartment in genetically-engineered mice results in systemic organ autoimmunity [94]. Numerous autoimmune conditions enter remission as a result of increased Treg number and/or activity, whereas relapse is associated

with reduction in number and/or activity. Specifically, this has been demonstrated in multiple sclerosis [95-99], rheumatoid arthritis [100-104], and lupus [105-107]. Given the importance of Treg cells in the control of autoimmunity, it would be useful to possess sources of Treg cells that are easily accessible and can be reintroduced into the patient for immune modulation. It has been previously demonstrated that high numbers of Treg cells are found in adipose tissue at concentrations much higher than other peripheral compartments such as blood or spleen [108]. Interestingly, adipose derived Treg contain approximately 100 fold higher concentrations of the immune regulatory effector cytokine IL-10 [109,110]. It is known that the adipose derived cytokines leptin and TNF-alpha inhibit Treg proliferation and activity in vivo [111,112]. The local effects of these cytokines would conceptually, be negated by liberating Treg from fat tissue followed by systemic re-administration, resulting in enhanced Treg activity. Administration of a large number of Treg cells with augmented in vivo proliferative and functional potential may result in a reduction of the threshold needed to attain tolerance to an ongoing immune response. For example, anti-CD3 antibodies have been reported to induce antigen-specific tolerance, despite the fact that the surge in Treg numbers was not antigen-specific [113]. Thus one conceptual advantage of utilizing SVF therapy would be not only the MSC content, which possesses various regenerative properties, but also Treg, which would enhance anti-inflammatory/tolerance inducing properties. Given that both MSC and Treg are considered to be tolerance-promoting, it may be feasible to consider that synergize of tolerance induction may be occurring when the two cell populations are co-administered in the form of SVF.

Endothelial progenitor cell (EPC)

Aging and/or damaged blood vessel endothelium is constantly renewed by circulating cells termed endothelial progenitor cells (EPC). This notion gathered significant scientific following subsequent to a paper by Asahara et al. who demonstrated that BM-originating cells expressing VEGFR-2 and CD34 are capable of incorporating into sites of angiogenesis induced by wire injury or ischemia [114]. Therapeutic properties of EPC have been demonstrated in that administration of exogenous EPC increases vascular repair. This has been shown using in vitro generated EPC, or bone marrow as a source of EPC in myocardial infarct [115,116], stroke [117], lung injury [118-120], liver failure [121-123], and endothelial injury atherosclerotic models [124,125]. Furthermore, administration of growth factors that stimulate mobilization of bone marrow stem cells and EPC have demonstrated therapeutic benefit in animal models of ischemic disease [126,127] as well as endothelial damage [128]. Clinical trials using EPC or bone marrow as a source of EPC for cardiovascular conditions [129-132], have demonstrated some therapeutic benefit, although work is ongoing.

Historically, the bone marrow has been used as a source of EPC, however, numerous recent studies have demonstrated a high content of EPC in adipose tissue [133,134]. Functional demonstration of adipose EPC was performed in experiments in which CD34 expressing cells were sorted for from SVF. This cellular fraction was demonstrated to induce angiogenesis in immune compromised mice that were subjected to hindlimb ischemia. Mechanistically, the cells were identified as EPC based on ability to form endothelial colonies when cultured in vitro [135]. Numerous groups have reported that SVF contains cellular activity that stimulates angiogenesis, for example, Sumi et al. showed that administration of SVF but not adipocytes led to revascularization in the hindlimb ischemia model [136]. Other studies have shown that not only are EPC-like activities found in SVF [137], but also that conditioned media from SVF is capable of stimulating host angiogenesis [138,139]. It is reported that EPC in the SVF stimulate angiogenesis directly through differentiating into endothelial cells

or through release of growth factors such as IGF-1, HGF-1 and VEGF [136,137,139-140]. Although back-to-back comparisons of bone marrow and adipose derived EPC for assessing angiogenic potential have not been performed, the substantially higher concentration of these cells in SVF supports the investigation of this tissue as a practical cell source for clinical applications.

Rationale for clinical applications

Given that SVF represents a multi-cellular population containing MSC, Treg, and EPC, the potential for therapeutic utilization would include many conditions that require regeneration, immune modulation, and possibly angiogenesis.

We previously reported remission in a patient with rheumatoid arthritis who was treated with autologous SVF [29]. Animal studies using the collagen II model of RA have demonstrated that administration of MSC is associated with immune modulation [141-143], disease remission [144,145], and regeneration of cartilage [5,146]. Additionally, our group and others have reported that Treg cells are associated with induction of disease remission [100-102,104, 147-151].

Safety data

The study was a retrospective analysis of patients treated under the practice of medicine under doctor patient privilege. The protocols were approved by local and institutional committees and all patients signed informed consent forms explaining the unproven and experimental nature of the treatment. Retrospective chart analysis of the patients was approved by PEARL IRB (Indianapolis, Indiana).

Patients received the indicated amount of cells by intravenous injection (2×10^6 cells per ml diluted in Saline solution), intra-articular injection (2.5×10^6 cells per ml in each injured joint, diluted in Saline solution and the patient's own serum). Multiple injections of cells were given to increase the therapeutic efficacy. Follow-ups were performed for all patients at 1, 3, 6 and 12 months.

SVF cells were isolated and prepared under the guidelines of Good Tissue Practices 21 CFR 1271 as relates to sample screening and processing in the sterile flow hood, inside of a class 10000 clean room. SVF cells were isolated by first washing 500 cc of lipoaspirate with PBS and subsequently, the cells were transferred to 175 ml sterile centrifuge containers followed by the addition of collagenase solution for a final concentration of 0.048%. The centrifuge containers were sealed and placed in an elliptical shaker and incubated at 37 C for 60–80 minutes. The content of the tubes was filtered through a cell strainer into sterile 50 ml centrifuge tubes and centrifuged for 12 min at 800 rcf. During centrifugation, SVF cells formed a pellet in the bottom of the container while the adipocyte layer and debris remained suspended. Following centrifugation, the stromal cells were resuspended in 5 mL of autologous serum for enzyme inactivation then washed 2 times with PBS. The fraction used for intraarticular injection was incubated with buffer to lyse red blood cells and washed once more. All the cells were aliquoted in cryovials, frozen in liquid nitrogen and stored until use. Cells were assessed for viability, endotoxin, and contamination before treatment was performed. The patient was allowed to heal from the liposuction for one week. For each treatment session, after thawing the cells were rinsed with PBS and Human AB serum, diluted in saline solution and autologous serum, loaded into sterile syringes, and then

transported in a controlled temperature cooler accompanied by the corresponding certificate and delivered to the physician for infusion.

Thirteen patients with rheumatoid arthritis were treated with 38–148 million SVF cells intravenously and intra-articularly (Table 1). Although no hematopoietic or biological abnormalities were noted, one of the patients reported facial flushing, fever and myalgia after a third of four injections. These symptoms all resolved spontaneously.

Table 1 Patient Treatments and Safety Outcome

Date of Birth	Date Treated	Total SVF Dose ($\times 10^6$) & route of injection * (SVF Dose \times no. injections)	Side Effects
6/24/1975	3/2/2010	128 IV (32 \times 4)	Facial flushing, fever, myalgia (resolved after 3 rd injection)
1/15/1950	9/27/2010	120 IV (40 \times 3)	None
4/10/1954	5/26/2010	90 IV (30 \times 3)	None
7/4/1967	7/22/2010	60 IV (30 \times 2) 12 IA (6 \times 2)	None
11/29/1950	7/26/2010	60 IV (20 \times 3) 6 IA (6 \times 1)	None
7/3/1956	11/3/2010	60 IV (24 \times 1, 18 \times 2)	None
6/1/1942	9/6/2010	90 IV (30 \times 3)	None
5/3/1940	4/26/2010	80 IV (40 \times 2) 32 IA (16 \times 2)	None
3/20/1941	8/11/2008	54 IV (27 \times 2)	None
3/25/1942	5/5/2008	108 IV (36 \times 3)	None
3/5/1963	2/26/2008	99 IV (33 \times 3)	None
1/15/1966	8/28/2008	90 IV (45 \times 2)	None
2/9/1952	9/30/2009	48 (30 \times 1, 18 \times 1)	None

* IV = intravenous, IA = intra-articular

Conclusion

These data suggest the safety and feasibility of administering adipose SVF intravenously. The uses of adipose stem cells have been reported in conditions as diverse as from hearing loss [152], to heart failure [153]. Given the anti-inflammatory, differentiation ability, and trophic factor production by SVF, we are hopeful that these safety data will support ongoing investigation into this novel and easy to access cell population.

Authors' contribution

JPR, MPM, SH, MM, KLM, BM, RJH, CC, RBT, AMM, and NHR performed literature review and wrote the manuscript. SH collected and analyzed patient charts. JPR reported on the clinical cases. NHR, conceived the study and rationale for use of SVF in autoimmunity. All authors read and approved the final manuscript.

Competing interests

NHR and JPR are shareholders of Medistem Panama and Medistem Inc. None of the other authors have any competing interests.

References

1. Kim ES, *et al*: **Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates escherichia coli-induced acute lung injury in mice.** *Respir Res* 2011, **12**(1):108.
2. Roddy GW *et al*: **Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TSG-6.** *Stem Cells* 2011, **29**: p. 1572–9.
3. Sun CK, *et al*: **Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model.** *J Transl Med* 2011, **9**:118.
4. Weil BR, *et al*: **Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia.** *Shock* 2011, **36**(3):235–241.
5. Macdonald GI, Augello A, De Bari C: **Mesenchymal stem cells: re-establishing immunological tolerance in autoimmune rheumatic diseases.** *Arthritis and Rheumatism* 2011, **63**(9):2547–2557.
6. Choi H, *et al*: **Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF- κ B signaling in resident macrophages.** *Blood* 2011, **118**(2):330–338.
7. Ringden O, Le Blanc K: **Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages Best practice & research.** *Clin Haem* 2011, **24**(1):65–72.
8. Dazzi F, Krampera M: **Mesenchymal stem cells and autoimmune diseases. Best practice & research.** *Clin Haem* 2011, **24**(1):49–57.
9. Vassalli G, Moccetti T: **Cardiac repair with allogeneic mesenchymal stem cells after myocardial infarction.** *Swiss Med Weekly* 2011, **141**:13209.
10. Poncelet AJ, *et al*: **Intracardiac allogeneic mesenchymal stem cell transplantation elicits neo-angiogenesis in a fully immunocompetent ischaemic swine model.** *European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery* 2010, **38**(6):781–787.
11. Chen L, *et al*: **Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice.** *PLoS One* 2009, **4**(9):e7119.
12. Weiss ML, *et al*: **Immune properties of human umbilical cord Wharton's jelly-derived cells.** *Stem Cells* 2008, **26**(11):2865–2874.

13. Lin YT, *et al*: **Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in huntington's disease mouse models.** *PLoS One* 2011, **6**(8):e22924.
14. Shabbir A, *et al*: **Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair.** *Am J Physiol Heart Circ Physiol* 2010, **299**(5):H1428–1438.
15. Khoo ML, *et al*: **Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents.** *PLoS One* 2011, **6**(5):e19025.
16. Hu S, *et al*: **Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: a single-center, randomized, double-blind, placebo-controlled clinical trial.** *J Am Coll Cardiol* 2011, **57**(24):2409–2415.
17. Williams AR, *et al*: **Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling.** *Circ Res* 2011, **108**(7):792–796.
18. Adler DS, *et al*: **Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy.** *Front Biosci* 2011, **3**:506–514.
19. Subrammaniyan R, *et al*: **Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience.** *Cytotherapy* 2011, **13**(8):993–999.
20. Gabr H, *et al*: **Limb salvage using intramuscular injection of unfractionated autologous bone marrow mononuclear cells in critical limb ischemia: a prospective pilot clinical trial.** *Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation* 2011, **9**(3):197–202.
21. Murphy MP, *et al*: **Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia.** *Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter* 2011, **53**(6):1565–1574e1.
22. Jiang R, *et al*: **Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study.** *Front Med* 2011, **5**(1):94–100.
23. Davatchi F, *et al*: **Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients.** *Int J Rheum Dis* 2011, **14**(2):211–215.
24. Honmou O, *et al*: **Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke.** *Brain:J Neurol* 2011, **134**(Pt 6):1790–1807.
25. Karussis D, *et al*: **Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.** *Arch Neurol* 2010, **67**(10):1187–1194.

26. Chen Y, Wang G, Zeng L: **Adipose tissue or bone marrow, store for purchasing mesenchymal stem cells?** *Circulation journal: official journal of the Japanese Circulation Society* 2011, **75**(9): 2260–8.
27. Mirsaidi A et al.: **Telomere length, telomerase activity and osteogenic differentiation are maintained in adipose-derived stromal cells from senile osteoporotic SAMP6 mice.** *Journal of tissue engineering and regenerative medicine* 2011 Jun 28 [Epub ahead of print].
28. Chen HT et al.: **Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures.** *Journal of cellular and molecular medicine* 2011 May 5 [Epub ahead of print].
29. Ichim TE, et al: **Autologous stromal vascular fraction cells: a tool for facilitating tolerance in rheumatic disease.** *Cell Immunol* 2010, **264**(1):7–17.
30. Hollenberg CH, Vost A: **Regulation of DNA synthesis in fat cells and stromal elements from rat adipose tissue.** *J Clin Invest* 1969, **47**(11):2485–2498.
31. Gaben-Cogneville AM, et al: **Differentiation under the control of insulin of rat preadipocytes in primary culture. Isolation of homogeneous cellular fractions by gradient centrifugation.** *Biochim Biophys Acta* 1983, **762**(3):437–444.
32. Zuk PA, et al: **Multilineage cells from human adipose tissue: implications for cell-based therapies.** *Tissue Eng* 2001, **7**(2):211–228.
33. Zuk PA, et al: **Human adipose tissue is a source of multipotent stem cells.** *Mol Biol Cell* 2002, **13**(12):4279–4295.
34. Faustini M, et al: **Nonexpanded mesenchymal stem cells for regenerative medicine: yield in stromal vascular fraction from adipose tissues.** *Tissue Eng Part C, Methods* 2010, **16**(6):1515–1521.
35. Garcia-Olmo D, et al: **A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation.** *Dis Colon Rectum* 2005, **48**(7):1416–1423.
36. Stillaert FB, et al: **Human clinical experience with adipose precursor cells seeded on hyaluronic acid-based spongy scaffolds.** *Biomaterials* 2008, **29**(29):3953–3959.
37. Garcia-Olmo D, Garcia-Arranz M, Herreros D: **Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease.** *Expert Opin Biol Ther* 2008, **8**(9):1417–1423.
38. Fang B, et al: **Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells.** *Bone Marrow Transplant* 2006, **38**(5):389–390.
39. Fang B, et al: **Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis.** *Transplant Proc* 2007, **39**(5):1710–1713.

40. Fang B, *et al*: **Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease.** *Transplant Proc* 2007, **39**(10):3358–3362.
41. Hayashi O, *et al*: **Comparison of osteogenic ability of rat mesenchymal stem cells from bone marrow, periosteum, and adipose tissue.** *Calcif Tissue Int* 2008, **82**(3):238–247.
42. Noel D, *et al*: **Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials.** *Exp Cell Res* 2008, **314**(7):1575–1584.
43. Kim Y, *et al*: **Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia.** *Cell Physiol Biochem* 2007, **20**(6):867–876.
44. Ikegame Y, *et al*: **Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy.** *Cytotherapy* 2011, **13**(6):675–685.
45. Keyser KA, Beagles KE, Kiem HP: **Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation.** *Cell Transplant* 2007, **16**(5):555–562.
46. www.vet-stem.com. **Vet-Stem Cell Therapy: Arthritis in Dogs and Cats/Tendons, Ligaments & Joints in Horses.** Last accessed on 01-30-2012.
47. Black LL, *et al*: **Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial.** *Vet Ther* 2007, **8**(4):272–284.
48. Black LL, *et al*: **Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs.** *Vet Ther* 2008, **9**(3):192–200.
49. Lin K, *et al*: **Characterization of adipose tissue-derived cells isolated with the Celution system.** *Cytotherapy* 2008, **10**(4):417–426.
50. www.tissuegenesis.com. **Tissue Genesis, Inc.** Last accessed on 01-30-2012.
51. Hang-Fu L, Marmolya G, Feiglin DH: **Liposuction fat-fillant implant for breast augmentation and reconstruction.** *Aesthetic Plast Surg* 1995, **19**(5):427–437.
52. Klein AW: **Skin filling. Collagen and other injectables of the skin.** *Dermatol Clin* 2001, **19**(3):491–508.
53. Riordan NH, *et al*: **Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis.** *J Translational Med* 2009, **7**:29.
54. Knowlton D: **Fifth Annual Stem Cell Summit.** *IDrugs: Invest Drugs J* 2010, **13**(4):235–238.

55. Hare JM, *et al*: **A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.** *J Am Coll Cardiol* 2009, **54**(24):2277–2286.
56. Wernicke CM, *et al*: **Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases.** *Int Arch Med* 2011, **4**(1):27.
57. Baek SJ, Kang SK, Ra JC: **In vitro migration capacity of human adipose-derived mesenchymal stem cells and their expression of a distinct set of chemokine and growth factor receptors.** *Experimental & molecular medicine* 2011, **43**(10):596–603.
58. Shi M, *et al*: **Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice.** *Haematol* 2007, **92**(7):897–904.
59. Puglisi MA, *et al*: **Adipose tissue-derived mesenchymal stem cells and hepatic differentiation: old concepts and future perspectives.** *European Rev Med Pharmacol Sci* 2011, **15**(4):355–364.
60. Ding DC, Shyu WC, Lin SZ: **Mesenchymal stem cells.** *Cell Transplant* 2011, **20**(1):5–14.
61. Caplan AI, Dennis JE: **Mesenchymal stem cells as trophic mediators.** *J Cell Biochem* 2006, **98**(5):1076–1084.
62. Meirelles Lda S, *et al*: **Mechanisms involved in the therapeutic properties of mesenchymal stem cells.** *Cytokine Growth Factor Rev* 2009, **20**(5–6):419–427.
63. Uccelli A, *et al*: **Neuroprotective features of mesenchymal stem cells. Best practice & research.** *Clin Haem* 2011, **24**(1):59–64.
64. Lu Y, *et al*: **Mesenchymal stem cells protect islets from hypoxia/reoxygenation-induced injury.** *Cell Biochem Funct* 2010, **28**(8):637–643.
65. Murohara T, Shintani S, Kondo K: **Autologous adipose-derived regenerative cells for therapeutic angiogenesis.** *Curr Pharm Des* 2009, **15**(24):2784–2790.
66. Ichim TE, *et al*: **Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy.** *Cell Immunol* 2010, **260**(2):75–82.
67. Chen PM, *et al*: **Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells.** *J Biomed Sci* 2011, **18**:49.
68. Pittenger MF, *et al*: **Multilineage potential of adult human mesenchymal stem cells.** *Sci* 1999, **284**(5411):143–147.
69. Aust L, *et al*: **Yield of human adipose-derived adult stem cells from liposuction aspirates.** *Cytotherapy* 2004, **6**(1):7–14.
70. Premaratne GU, *et al*: **Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: anti-inflammatory role.** *J Cardiothorac Surg* 2011, **6**:43.

71. de la Garza-Rodea AS et al.: **Myogenic properties of human mesenchymal stem cells derived from three different sources.** *Cell transplantation* 2011 Jun 7 [Epub ahead of print].
72. Vidal MA et al.: **Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue, and umbilical cord tissue.** *Stem cells and development* 2012, **21**(2):273–283.
73. Mendelson A et al.: **Chondrogenesis by chemotactic homing of synovium, bone marrow, and adipose stem cells in vitro.** *The FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 2011, **25**(10):3496–504.
74. Tse KH et al.: **Adipose tissue and bone marrow-derived stem cells react similarly in an ischaemia-like microenvironment.** *Journal of tissue engineering and regenerative medicine* 2011 Jul 13 [Epub ahead of print].
75. Niemeyer P, et al.: **Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro.** *Tissue Eng* 2007, **13**(1):111–121.
76. Zhang X, et al.: **Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue.** *J Cell Biochem* 2011, **112**(4):1206–1218.
77. Najar M, et al.: **Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources.** *Cell Immunol* 2010, **264**(2):171–179.
78. Najar M, et al.: **Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor.** *Tissue Eng Part A* 2010, **16**(11):3537–3546.
79. Wagner W, Ho AD: **Mesenchymal stem cell preparations—comparing apples and oranges.** *Stem Cell Rev* 2007, **3**(4):239–248.
80. Ra JC, et al.: **Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans.** *Stem Cells Dev* 2011, **20**(8):1297–1308.
81. Vanikar AV, et al.: **Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: a novel therapy for insulin-dependent diabetes mellitus.** *Stem Cells Int* 2010, **2010**:582382.
82. Garcia-Olmo D, et al.: **Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial.** *Dis Colon Rectum* 2009, **52**(1):79–86.
83. Caimi PF, et al.: **Emerging therapeutic approaches for multipotent mesenchymal stromal cells.** *Curr Opin Hematol* 2010, **17**(6):505–513.
84. Singer NG, Caplan AI: **Mesenchymal stem cells: mechanisms of inflammation.** *Annual Rev Pathol* 2011, **6**:457–478.

85. Lindroos B, Suuronen R, Miettinen S: **The potential of adipose stem cells in regenerative medicine.** *Stem Cell Rev* 2011, **7**(2):269–291.
86. Cho KS, Roh HJ: **Immunomodulatory effects of adipose-derived stem cells in airway allergic diseases.** *Current Stem Cell Res Therapy* 2010, **5**(2):111–115.
87. Ringden O, *et al*: **Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.** *Transplant* 2006, **81**(10):1390–1397.
88. Le Blanc K, *et al*: **Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.** *Lancet* 2008, **371**(9624):1579–1586.
89. Fang B, *et al*: **Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease.** *Transplant Proc* 2007, **39**(10):3358–3362.
90. Fang B, *et al*: **Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis.** *Transplant Proc* 2007, **39**(5):1710–1713.
91. Chang X, Zheng P, Liu Y: **FoxP3: a genetic link between immunodeficiency and autoimmune diseases.** *Autoimmun Rev* 2006, **5**(6):399–402.
92. Bacchetta R, *et al*: **Defective regulatory and effector T cell functions in patients with FOXP3 mutations.** *J Clin Investig* 2006, **116**(6):1713–1722.
93. Schubert LA, *et al*: **Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation.** *J Biol Chem* 2001, **276**(40):37672–37679.
94. Rudensky AY, Regulatory T: **Cells and Foxp3.** *Immunol Rev* 2011, **241**(1):260–268.
95. Correale J, Villa A: **Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis.** *Ann Neurol* 2010, **67**(5):625–638.
96. Fransson M, *et al*: **T regulatory cells lacking CD25 are increased in MS during relapse.** *Autoimmunity* 2010, **43**(8):590–597.
97. Frisullo G, *et al*: **CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients.** *Hum Immunol* 2010, **71**(5):437–441.
98. Braitich M, *et al*: **Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis.** *Acta Neurol Scand* 2009, **119**(4):239–245.
99. Haas J, *et al*: **Reduced suppressive effect of CD4 + CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.** *Eur J Immunol* 2005, **35**(11):3343–3352.
100. Kavousanaki M, *et al*: **Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy.** *Arthritis Rheum* 2010, **62**(1):53–63.

101. Sempere-Ortells JM, *et al*: **Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity score-28.** *Autoimmunity* 2009, **42**(8):636–645.
102. Esensten JH, Wofsy D, Bluestone JA: **Regulatory T cells as therapeutic targets in rheumatoid arthritis.** *Nat Rev Rheumatol* 2009, **5**(10):560–565.
103. Flores-Borja F, *et al*: **Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis.** *Proc Natl Acad Sci USA* 2008, **105**(49):19396–19401.
104. Kao JK, Hsue YT, Lin Cy: **Role of new population of peripheral CD11c(+)CD8(+) T cells and CD4(+)CD25(+) regulatory T cells during acute and remission stages in rheumatoid arthritis patients.** *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi* 2007, **40**(5):419–427.
105. Zhang Y, *et al*: **White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models.** *Cancer Res* 2009, **69**(12):5259–5266.
106. Yan B, *et al*: **Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells.** *Arthritis Rheum* 2008, **58**(3):801–812.
107. Sfrikakis PP, *et al*: **Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.** *Clin Immunol* 2007, **123**(1):66–73.
108. Cipolletta D *et al*.: **Tissular T(regs): a unique population of adipose-tissue-resident Foxp3 + CD4+ T cells that impacts organismal metabolism.** *Seminars in immunology* 2011, **23**(6):431–7.
109. Feuerer M, *et al*: **Genomic definition of multiple ex vivo regulatory T cell subphenotypes.** *Proc Natl Acad Sci USA* 2010, **107**(13):5919–5924.
110. Feuerer M, *et al*: **Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters.** *Nature Med* 2009, **15**(8):930–939.
111. De Rosa V, *et al*: **A key role of leptin in the control of regulatory T cell proliferation.** *Immunity* 2007, **26**(2):241–255.
112. Valencia X, *et al*: **TNF downmodulates the function of human CD4 + CD25hi T-regulatory cells.** *Blood* 2006, **108**(1):253–261.
113. Chatenoud L: **CD3-specific antibody-induced active tolerance: from bench to bedside.** *Nat Rev Immunol* 2003, **3**(2):123–132.
114. Asahara T, *et al*: **Isolation of putative progenitor endothelial cells for angiogenesis.** *Sci* 1997, **275**(5302):964–967.
115. Kupatt C, *et al*: **Retroinfusion of embryonic endothelial progenitor cells attenuates ischemia-reperfusion injury in pigs: role of phosphatidylinositol 3-kinase/AKT kinase.** *Circulation* 2005, **112**(9 Suppl):I117–122.

116. Aicher A, *et al*: **Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling.** *Circulation* 2003, **107**(16):2134–2139.
117. Fan Y, *et al*: **Endothelial progenitor cell transplantation improves long-term stroke outcome in mice.** *Ann Neurol* 2010, **67**(4):488–497.
118. Lam CF, *et al*: **Transplantation of endothelial progenitor cells improves pulmonary endothelial function and gas exchange in rabbits with endotoxin-induced acute lung injury.** *Anesth Analg* 2011, **112**(3):620–627.
119. Mao M, *et al*: **Intravenous delivery of bone marrow-derived endothelial progenitor cells improves survival and attenuates lipopolysaccharide-induced lung injury in rats.** *Shock* 2010, **34**(2):196–204.
120. Kahler CM, *et al*: **Peripheral infusion of rat bone marrow derived endothelial progenitor cells leads to homing in acute lung injury.** *Respir Res* 2007, **8**:50.
121. Elkhafif N, *et al*: **CD133(+) human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis.** *APMIS: Acta Path, Micro, Im Scand* 2011, **119**(1):66–75.
122. Liu F, *et al*: **Transplanted endothelial progenitor cells ameliorate carbon tetrachloride-induced liver cirrhosis in rats.** *Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society* 2009, **15**(9):1092–1100.
123. Nakamura T, *et al*: **Significance and therapeutic potential of endothelial progenitor cell transplantation in a cirrhotic liver rat model.** *Gastroenterology* 2007, **133**(1):91–107 e1.
124. Wang SH, *et al*: **Late outgrowth endothelial cells derived from Wharton jelly in human umbilical cord reduce neointimal formation after vascular injury: involvement of pigment epithelium-derived factor.** *Arterioscler Thromb Vasc Biol* 2009, **29**(6):816–822.
125. Desouza CV, *et al*: **Role of inflammation and insulin resistance in endothelial progenitor cell dysfunction.** *Diabetes* 2011, **60**(4):1286–1294.
126. Orlic D, *et al*: **Mobilized bone marrow cells repair the infarcted heart, improving function and survival.** *Proc Natl Acad Sci USA* 2001, **98**(18):10344–10349.
127. Zhang L *et al*: **Granulocyte colony-stimulating factor treatment ameliorates liver injury and improves survival in rats with d-galactosamine-induced acute liver failure.** *Toxicology letters* 2011, **204**(1):92–9.
128. Cho HJ, *et al*: **Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation.** *Circulation* 2003, **108**(23):2918–2925.
129. Lara-Hernandez R, *et al*: **Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia.** *Ann Vasc Surg* 2010, **24**(2):287–294.

130. Kim DI, *et al*: **Angiogenesis facilitated by autologous whole bone marrow stem cell transplantation for Buerger's disease.** *Stem Cells* 2006, **24**(5):1194–1200.
131. Mund JA, *et al*: **Endothelial progenitor cells and cardiovascular cell-based therapies.** *Cytotherapy* 2009, **11**(2):103–113.
132. Katritsis DG, *et al*: **Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells.** *Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* 2007, **9**(3):167–171.
133. Auxenfans C *et al*.: **Adipose-derived stem cells (ASCs) as a source of endothelial cells in the reconstruction of endothelialized skin equivalents.** *Journal of tissue engineering and regenerative medicine* 2011 Jul 14 [Epub ahead of print].
134. Martinez-Estrada OM, *et al*: **Human adipose tissue as a source of Flk-1+ cells: new method of differentiation and expansion.** *Cardiovasc Res* 2005, **65**(2):328–333.
135. Miranville A, *et al*: **Improvement of postnatal neovascularization by human adipose tissue-derived stem cells.** *Circulation* 2004, **110**(3):349–355.
136. Sumi M, *et al*: **Transplantation of adipose stromal cells, but not mature adipocytes, augments ischemia-induced angiogenesis.** *Life Sci* 2007, **80**(6):559–565.
137. Planat-Benard V, *et al*: **Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives.** *Circulation* 2004, **109**(5):656–663.
138. Nakagami H, *et al*: **Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells.** *Arterioscler Thromb Vasc Biol* 2005, **25**(12):2542–2547.
139. Rehman J, *et al*: **Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells.** *Circulation* 2004, **109**(10):1292–1298.
140. Cai L, *et al*: **Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization.** *Stem Cells* 2007, **25**(12):3234–3243.
141. Bouffi C, *et al*: **IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis.** *PLoS One* 2010, **5**(12):e14247.
142. Mao F, *et al*: **Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis.** *Inflammation research: official journal of the European Histamine Research Society* 2010, **59**(3):219–225.
143. Gonzalez MA, *et al*: **Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells.** *Arthritis Rheum* 2009, **60**(4):1006–1019.
144. Liu Y, *et al*: **Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis.** *Arthritis Res Therapy* 2010, **12**(6):R210.

145. Augello A, *et al*: **Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis.** *Arthritis Rheum* 2007, **56**(4):1175–1186.
146. Miyamoto C, *et al*: **Osteogenic protein-1 with transforming growth factor-beta1: potent inducer of chondrogenesis of synovial mesenchymal stem cells in vitro.** *Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association* 2007, **12**(6):555–561.
147. de Kleer IM, *et al*: **CD4 + CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.** *J Immunol* 2004, **172**(10):6435–6443.
148. Popov I, *et al*: **Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine.** *Arthritis Res Therapy* 2006, **8**(5):R141.
149. Ichim TE, *et al*: **Antigen-specific therapy of rheumatoid arthritis.** *Expert Opin Biol Ther* 2008, **8**(2):191–199.
150. Zheng X, *et al*: **RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis.** *Arthritis Res Therapy* 2010, **12**(1):R13.
151. Zheng X, *et al*: **Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells.** *J Immunol* 2010, **184**(11):6457–6464.
152. Zhou Y, *et al*: **The therapeutic efficacy of human adipose tissue-derived mesenchymal stem cells on experimental autoimmune hearing loss in mice.** *Immunology* 2011, **133**(1):133–140.
153. Madonna R, De Caterina R: **Adipose tissue: a new source for cardiovascular repair.** *Journal Cardiovasc Med* 2010, **11**(2):71–80.